Arabic Arabic English English French French German German
dark

Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study

Eli Lilly and Company announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis over a 12-week induction treatment were maintained for up to one year. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

NeoDynamics receives first German order of pulse biopsy system NeoNavia

Next Post

Anivive Awarded $500,000 Grant by the FDA for Canine Cancer Studies

Related Posts
Total
0
Share